

A randomised, double-blind controlled trial of mometosone furoate cream versus placebo to prevent radiation dermatitis of the breast and chest wall

Submission date 07/07/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 07/07/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 24/01/2022	Condition category Signs and Symptoms	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<http://www.cancerhelp.org.uk/trials/a-trial-effect-using-steroid-cream-decrease-skin-reactions-caused-having-radiotherapy>

Contact information

Type(s)

Scientific

Contact name

Ms Helen Spickett

Contact details

Rosemere Cancer Centre
Royal Preston Hospital
Sharoe Green Lane
Fulwood
Preston
United Kingdom
PR2 9HT

-
helen.spickett@lscn.nhs.uk

Additional identifiers

Clinical Trials Information System (CTIS)

2006-002352-15

Protocol serial number

2191

Study information

Scientific Title

A randomised, double-blind controlled trial of mometasone furoate cream versus placebo to prevent radiation dermatitis of the breast and chest wall

Acronym

Skin Study

Study objectives

A prospective, double blind, randomised study investigating the effect of mometasone furoate on the prevention of radiation dermatitis of the breast and chest wall. Scoring systems include visual scoring and reflectance spectrometry. Participants receiving a 40 Gy, 15 fractionated, 3 week radical course of whole breast radiotherapy plus or minus breast boost will be eligible.

Ethics approval required

Old ethics approval format

Ethics approval(s)

MREC approved (ref: 06/Q0201/79)

Study design

Single centre randomised interventional process of care trial

Primary study design

Interventional

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Breast Cancer; Disease: Breast

Interventions

Placebo or mometasone furoate. Assessments are taken at baseline, day 8, 15, 21, 29, 36 and 43.

Study entry: single randomisation only

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Mometasone furoate

Primary outcome(s)

Change in visual skin assessment

Key secondary outcome(s)

1. Objective skin assessment
2. Changes in quality of life measures

Completion date

31/07/2011

Eligibility

Key inclusion criteria

1. Aged 18 years or over, either sex
2. Receiving 40 Gy 15 fractionated, 3 week radical radiotherapy to the breast or chest wall
3. Patient provides informed consent to participate in the study and completes follow up

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Skin involvement of disease
2. Untreated bacterial, fungal or viral skin lesions
3. Inability to self administer creams

Date of first enrolment

02/11/2009

Date of final enrolment

31/07/2011

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Rosemere Cancer Centre
Preston
United Kingdom
PR2 9HT

Sponsor information

Organisation
Lancashire Teaching Hospitals NHS Trust (UK)

ROR
<https://ror.org/02j7n9748>

Funder(s)

Funder type
Charity

Funder Name
Rosemere Cancer Foundation (UK)

Results and Publications

Individual participant data (IPD) sharing plan
Not provided at time of registration

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		15/11/2014	24/01/2022	Yes	No
Plain English results			24/01/2022	No	Yes